Evaluating biomarkers, such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor‐2 (HER2), in pathological specimens is crucial for guiding breast cancer treatment. Here, ESR1 is linked to breast cancer.